Bayesian Health vs VUNO (2026)
Both predict dangerous events for patients on hospital wards, with different targets and different regulators. Bayesian Health, a Johns Hopkins spinout, reads the EHR continuously and flags inpatients at rising risk of sepsis, preparing order sets and documentation; its sepsis module is FDA cleared. VUNO, a Seoul company, leads with DeepCARS, which predicts in hospital cardiac arrest within 24 hours from four routinely charted vital signs and returns a 0 to 100 risk score for ward staff and rapid response teams. It is approved in Korea and CE marked, and in the United States it holds FDA Breakthrough Device designation, which is not a clearance. Choose Bayesian for sepsis in the United States; choose DeepCARS for cardiac arrest warnings where it is approved.
- Sepsis is the risk you are watching, and you need an FDA clearance.
- Alerts should come with order sets and documentation ready.
- You may add modules for deterioration or readmissions later.
- Cardiac arrest on general wards is the risk you are watching.
- The model should need only four routinely charted vital signs.
- You operate in Korea or Europe, where the product is approved.
This comparison is published by AI Health Index, an independent research platform that compares healthcare AI vendors objectively. Bayesian Health and VUNO are each graded against the same capability taxonomy, from each vendor's own public materials and the regulatory record, under the AI Health Index verification standard. No vendor pays for placement, and no vendor has reviewed this page. How this evidence is graded
Plain facts
| Fact | Bayesian Health | VUNO |
|---|---|---|
| Primary category | Inpatient Deterioration & Risk Monitoring | Clinical Decision Support |
| Founded | 2018 | 2014 |
| Headquarters | New York, New York, United States | Seoul, South Korea |
| Website | bayesianhealth.com | vuno.co |
Side by Side
Select any grade to read the note behind it.
Product updates
The latest logged changes from each vendor, newest first, each linked to its source.
Bayesian Health
-
Regulatory / FDA
CMS approved a New Technology Add-on Payment for Bayesian Health's FDA cleared continuous AI sepsis monitor, creating Medicare payment support for health systems running the platform.
Source
VUNO
-
Clinical evidence
Researchers from VUNO published a peer-reviewed study in the American Journal of Neuroradiology validating a machine learning algorithm that uses automated brain MRI volumetry to differentiate frontotemporal dementia from Alzheimer's disease.
Source
Each vendor in one paragraph
Written to be quoted whole. Each paragraph opens the AI Health Index profile of the vendor: what the product is, who buys it and what it does.
Bayesian Health, a Johns Hopkins spinout founded by Suchi Saria, sells a platform of machine learning models that read the EHR continuously and flag inpatients at rising risk, with workflows that prepare order sets and documentation for clinicians to act on. Its lead module detects sepsis early.
Source: AI Health Index, September 2026
VUNO, a Seoul medical AI company founded in 2014, leads with DeepCARS, which predicts in-hospital cardiac arrest within 24 hours for patients on general wards from four routinely charted vital signs: blood pressure, heart rate, respiratory rate and temperature. It returns a 0 to 100 risk score for ward staff and rapid response teams to act on, and the company describes it as Korea's first AI medical device for this purpose.
Source: AI Health Index, September 2026
Questions buyers ask
How are Bayesian Health and VUNO priced and sold?
For Bayesian Health, the product is sold to health systems as an enterprise platform, by module, with implementation that tunes models to each site.
With VUNO, the company's history page records that in 2022 DeepCARS became the first AI medical device to enter Korea's non-reimbursed market, and the first designated under the country's early access medical technology route: hospitals can charge patients for it as a non-covered service while its formal evaluation continues. From the AI Health Index, drawn from each vendor's own published materials and the regulatory record, verified September 29, 2026. No vendor pays for placement.
How do Bayesian Health and VUNO handle patient data?
In Bayesian Health's case, the company's privacy policy covers its marketing website. Nothing published states what patient data is retained, for how long, whether one health system's data develops models used by others, or who inside the company can reach identified records.
For VUNO, the policy does not say whether information processed for a hospital is pseudonymized and used to develop the company's models, or whether a hospital can decline that use. From the AI Health Index, drawn from each vendor's own published materials and the regulatory record, verified September 29, 2026. No vendor pays for placement.
What evidence is published for Bayesian Health and VUNO?
With Bayesian Health, the company's own clearance study (K250680) adds a retrospective validation on 7,732 encounters at four hospitals.
In VUNO's case, the multicenter validation of 173,368 patients, published in Resuscitation in 2021 and cited on the DeepCARS page, reports an area under the curve of 0.860 internally and 0.905 externally. From the AI Health Index, drawn from each vendor's own published materials and the regulatory record, verified September 29, 2026. No vendor pays for placement.
How much do Bayesian Health and VUNO leave to the clinician?
For Bayesian Health, the company's published studies treated clinician response as part of the system: providers confirm or dismiss each alert, and the Nature Medicine outcome study measured outcomes by whether an alert was confirmed within three hours. On top of the flag, the company now describes agentic workflows that tee up order sets, pathway steps and documentation and track bundle completion, with the clinician acting.
With VUNO, the score runs from 0 to 100 for the risk of cardiac arrest in the general ward within 24 hours, and the company positions the tool as enabling timely intervention rather than triggering automated escalation; nursing staff, not the algorithm, mobilize the response. From the AI Health Index, drawn from each vendor's own published materials and the regulatory record, verified September 29, 2026. No vendor pays for placement.
Related comparisons
Other published head to head assessments involving these vendors or their closest peers. The full set for this category is on the Clinical Decision Support page.
Both records were reviewed on this site in September 2026. Neither publishes a price. DeepCARS's US status is a Breakthrough Device designation, not a clearance, and no lead time was found in what was read of Bayesian's clearance.
Ask both how many hours of warning a clinician gets, and how many alerts come with it.